Biocon receives approval for insulin glargine in in Mexico

Biocon Ltd has announced that its insulin glargine has been approved by Cofepris, the Mexican health authority, through its partner PiSA Farmaceutica. Mexico has been a very important market for Biocon since 2006, where it has been playing a significant role in enabling access to affordable rh-insulin. Insulin glargine will augment the affordable insulins therapy for diabetes management. Galactus by PiSA is the first insulin glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012.
 
Biocon is recognised as Asia’s largest insulins producer and has been committed to affordable diabetes management through rh-insulin (Insugen) and insulin glargine (Basalog) in India and several emerging markets. The company currently has marketing approvals in over 60 countries for rh-Insulin and in over 20 countries for Insulin Glargine.
 
Kiran Mazumdar-Sha, chairperson & managing director, Biocon, said, “We are committed to make global impact with our affordable insulins therapy. Our insulin glargine, will now enable access to a basal insulin which will further expand the diabetes management therapy for patients in Mexico.”
 
Ravi Limaye, president - marketing, Biocon, said, “With insulin glargine approval in Mexico we have expanded our insulins global footprint. Along with our partner PiSA we will be able to enhance the reach of our affordable insulins therapy in the country.”